Monitoring serum pregabalin (Lyrica) concentrations, assessing compliance, and adjusting dosage in patients
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Lyrica, Pregabalin
Serum
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Collect specimen immediately before next scheduled dose.
2. Within 2 hours of collection, centrifuge, and aliquot serum into a plastic vial.
If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.
0.5 mL
Gross hemolysis | OK |
Gross lipemia | OK |
Gross icterus | OK |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 28 days | |
Ambient | 28 days | ||
Frozen | 28 days |
Monitoring serum pregabalin (Lyrica) concentrations, assessing compliance, and adjusting dosage in patients
Pregabalin (Lyrica) is an anticonvulsant drug used to treat partial seizures in patients and is a more potent successor to gabapentin. Pregabalin is commonly used for neuropathic pain and fibromyalgia. This test can be used by healthcare providers to assess compliance and may be clinically useful in patients with kidney failure who generally require lower dosages. Therapeutic and toxic ranges are not well defined. Therapeutic concentrations are reportedly 2 to 5 mcg/mL, while toxicity may occur at concentrations above 10 mcg/mL.
2.0-5.0 mcg/mL
The serum concentration should be interpreted in the context of the patient's clinical response and other clinical tests. This may provide useful information for patients showing poor response, noncompliance, or adverse effects. Toxicity can occur with concentrations greater than or equal to 10 mcg/mL.
This test cannot be performed on whole blood.
1. Baselt R: Disposition of Toxic Drugs and Chemicals in Man. 10th ed. Biomedical Publications; 2014
2. Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry, 2018;51(1-02):9-62
Samples are extracted and followed with analyte detection by mass spectrometry.(Unpublished Mayo method)
Monday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
80299
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
PGN | Pregabalin, S | 47414-8 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
65119 | Pregabalin, S | 47414-8 |